Abstract:Chinese materia medica (CMM) has been applied for the prevention and treatment of diseases for thousands of years. However, arrhythmia, myocardial ischemia, heart failure, and other cardiac adverse reactions during CMM application were gradually reported. CMM-induced cardiotoxicity has aroused widespread attention. Our review aimed to summarize the risk compounds, preclinical toxicity evaluation, and potential mechanisms of CMM-induced cardiotoxicity. All relevant articles published on the PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases for the latest twenty years were searched and manually extracted. The risk substances of CMM-induced cardiotoxicity are relatively complex. A single CMM usually contains various risk compounds, and the same risk substance may exist in various CMM. The active and risk substances in CMM may be transformed into each other under different conditions, such as drug dosage, medication methods, and body status. Generally, the risk compounds of CMM-induced cardiotoxicity can be classified into alkaloids, terpenoids, steroids, heavy metals, organic acids, toxic proteins, and peptides. Traditional evaluation methods of chemical drug-induced cardiotoxicity primarily include cardiac function monitoring, endomyocardial biopsy, myocardial zymogram, and biomarker determination. In the preclinical stage, CMM-induced cardiotoxicity should be systematically evaluated at the overall, tissue, cellular, and molecular levels, including cardiac function, histopathology, cytology, myocardial zymogram, and biomarkers. Thanks to the development of systematic biology, the higher specificity and sensitivity of biomarkers, such as genes, proteins, and metabolic small molecules, are gradually applied for evaluating CMM-induced cardiotoxicity. Previous studies on the mechanisms of CMM-induced cardiotoxicity focused on a single drug, monomer or components of CMM. The interaction among ion homeostasis (sodium, potassium, and calcium ions), oxidative damage, mitochondrial injury, apoptosis and autophagy, and metabolic disturbance is involved in CMM-induced cardiotoxicity. Clarification on the risk compounds, preclinical toxicity evaluation, and potential mechanisms of CMM-induced cardiotoxicity must be beneficial to guide new CMM development and post-marketed CMM reevaluation.

Summary and Analysis of Safety Warning on Clinical Application of Chinese Patent Medicine Preparations for Coronary Heart Disease

[Analysis on the Common Causes for Traditional Chinese Medicinal Injection Induced Adverse Reactions and the Preventive Countermeasures].

[Summary and analysis of safety warning on clinical application of anti-cold Chinese patent medicine preparations]

'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors

Notice for Western Medicine Physicians in Clinical Use of Chinese Patent Drugs

Analysis of 136 ADRs Induced by Chinese Patent Medicine

[Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines]

Analysis of Adverse Reaction of Common Chinese Herbs with Antirheumatic Activity

[Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use]

[Analysis of adverse reactions risk signal of Xinyuan Capsules based on national ADR monitoring spontaneous reporting system]

[Establishment and Verification of Risk Assessment Scale for Clinical Safety Medication of Aconitine].

Acute and Chronic Liver Injury Induced by Chinese Patent Medicine: Causes and Precautions

Investigation and Analysis on Comments of Prescriptions Containing Chinese Patent Medicines

[Evaluation and consideration on safety information abroad of Polygonum multiflorum and its preparations]

Analysis of Prescriptions on the Compatibility of Chinese Patent Medicines Containing Salvia Miltiorrhiza,Radix Et Rhizoma Glycyrrhizae and Radix Et Rhizoma Rhei with Western Medicines

Adverse Reaction of Commonly Used Anti-Hypertensives and Safety Countermeasure on Clinic

Recent advances in Chinese patent medicines entering the international market

The exploration on criteria and compromise in the prescription review of Chinese patent medicines X: medication for children

[Pharmacovigilance guidelines of Chinese patent medicines]

The Characteristics and Regularities of Cardiac Adverse Drug Reactions Induced by Chinese Materia Medica: A Bibliometric Research and Association Rules Analysis.

Risk Compounds, Preclinical Toxicity Evaluation, and Potential Mechanisms of Chinese Materia Medica–Induced Cardiotoxicity